Blood markers may spot delirium risk in elderly heart patients
NCT ID NCT07302737
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether certain blood markers can predict delirium (sudden confusion) in older adults with heart failure. Researchers will compare two markers: one for inflammation (SII) and one for blood sugar and fat levels (TyG). They aim to find a simple way to identify high-risk patients early, potentially preventing complications. The study will involve 100 participants and track their hospital outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Aug 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
hospitalized older adults with heart failure
- Ages
-
60 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Heart failure stage C Exclusion Criteria: 1. cognitive impairment 2. Major Neurological Conditions: (e.g., stroke, traumatic brain injury). 3. Hematological diseases that affect platelet, neutrophil, and lymphocyte counts. 4. Cardiogenic Shock 5. Sepsis 6. Ongoing Treatment with Immunosuppressants, or corticosteroids
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Delirium confusional state are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Ain Shams University hospitals
Cairo, 11566, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an inhaler boost heart pumping in COPD patients?
- Can zapping the heart beat drugs for AF in heart failure?
- Which SGLT2 inhibitor wins? trial pits empagliflozin against dapagliflozin
- Can daily mindful breathing ease heart failure symptoms?
- Can a smartphone app keep heart failure patients out of the hospital?
- Can better training get doctors to talk about what matters most to dying veterans?